Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial Forty-three evaluable patients with common/pre-B (n ...

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

The study showed that having pre-existing leukopenia and more favorable performance status was associated with a higher risk of rash. Having a certain laboratory abnormality may be an indicator of ...

Data from this new study suggest that tailoring induction therapy for acute myeloid leukemia (AML) based on cytarabine pharmacogenomic 10–single-nucleotide variant score could better treatment for ...

Please provide your email address to receive an email when new articles are posted on . Concomitant use of common medications did not significantly affect treatment efficacy or safety during UC ...

CHICAGO -- Patients with undetectable disease after induction therapy for newly diagnosed multiple myeloma (NDMM) did not have significantly better outcomes with a stem-cell transplant versus drug ...

Even in nonproliferative class 1-2 LN, glucocorticoid monotherapy may be insufficient to prevent long-term renal damage. Combination therapy should be considered. Patients with class 1-2 lupus ...